Audio
Clinical Professionals
Gepant Pharmacokinetics, Hepatic Dosing, and Drug Interactions
Outlines gepant metabolism and dosing, with emphasis on ubrogepant and rimegepant interactions, hepatic adjustment, renal limitations, and practical prescribing precautions.
This resource is private and requires a subscriber login to stream. SIGN IN to continue.
Duration
00:02:40
File size
0.61 MB
Practitioner-Guided Note
Reconcile all CYP3A4 and transporter interactions before prescribing a gepant, adjust for hepatic impairment, and avoid giving false reassurance when end-stage renal disease removes the evidence base.
Key Takeaways
Ubrogepant is primarily metabolized through CYP3A4; Strong CYP3A4 inhibitors can make ubrogepant unsafe without dose change or avoidance; Moderate hepatic impairment changes gepant exposure and may alter dosing; End-stage renal disease remains a major reason to avoid ubrogepant; Transporter and grapefruit interactions matter in real-world gepant prescribing